AstraZeneca (LON:AZN) Stock Passes Above 200-Day Moving Average – What’s Next?

Shares of AstraZeneca PLC (LON:AZN) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of £114.96 ($142.61) and traded as high as £119.78 ($148.59). AstraZeneca shares last traded at £117.86 ($146.21), with a volume of 2,997,711 shares trading hands.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on AZN shares. JPMorgan Chase & Co. restated an “overweight” rating and issued a £140 ($173.68) target price on shares of AstraZeneca in a report on Friday, November 22nd. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 140 ($1.74) price objective on shares of AstraZeneca in a research note on Monday, January 27th. Finally, Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and a consensus target price of GBX 7,935.67 ($98.45).

AstraZeneca Stock Down 1.6 %

The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. The company has a 50-day simple moving average of £107.76 and a 200 day simple moving average of £114.98. The company has a market cap of £179.80 billion, a P/E ratio of 3,682.54, a P/E/G ratio of 0.86 and a beta of 0.17.

Insider Buying and Selling

In other news, insider Pascal Soriot purchased 20,000 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were acquired at an average price of £102.03 ($126.57) per share, with a total value of £2,040,600 ($2,531,447.71). Also, insider Tony Mok acquired 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average price of £126.80 ($157.30) per share, with a total value of £190,200 ($235,950.87). 0.04% of the stock is currently owned by insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.